ARCHIVES

FDA Approval of Abraxane Sets Stage for Competition Between Taxane Drugs. Abraxane a Nanotechnology Drug? Sponsor Says Yes, FDA Says.

This article is from The Cancer Letter archive.

Vol. 31 No. 02 | January 14, 2005

Download PDF Visit The Full Archive

Related Articles

Researchers Link Obesity With 34% Higher Death Risk In Pre-Menopausal Women

May 30, 2014

In Brief: Wells Tapped For GM Cancer Foundation; Calder Named NABCO Associate Director

January 17, 1997

In Brief: NCAB to Hear Program Review, Reports On AIDs Monoclonal Antibodies, Cancer Research at Drew

November 25, 1983

Four RFAs Released For RM Program

November 6, 1981

NCI director says rules hurt retention, recruitment, cites Liotta’s departure.

April 8, 2005

Phase III Trial of Alimta, Avastin Combination Fails Endpoint to Improve Overall Survival

September 28, 2012